City
Epaper

India's pharma exports clock double-digit growth amid surging demand in US, UK

By IANS | Updated: June 18, 2024 13:00 IST

New Delhi, June 18 India’s pharmaceutical exports continue to register double-digit growth, reflecting the strong demand for the ...

Open in App

New Delhi, June 18 India’s pharmaceutical exports continue to register double-digit growth, reflecting the strong demand for the country’s affordable generic medicines in global markets led by the USA and UK.

India’s pharma exports grew by 10.45 per cent in May this year to touch the $2.3 billion mark compared with the $2.08 billion in the same month of the previous financial year.

“It is moving in a positive way and we are optimistic of sustaining growth of not less than 10 per cent,” Director General, Pharmaceuticals Export Promotion Council of India, Ravi Uday Bhaskar said on the quick estimate numbers released last week by the Centre.

India is now the world's third-largest drugmaker by volume amid the growing demand for the country’s pharmaceutical products in export markets.

The US is a key market, which accounts for about 30 per cent of India's annual pharma exports after a nearly 16 per cent increase in fiscal 2024, according to Pharmexcil.

The country's drug shortages as well as the increased use of drugs for lifestyle diseases such as diabetes, hypertension and depression is expected to fuel the demand for India's affordably priced drugs, according to Bhaskar.

According to a report by India Ratings and Research, Indian drugmakers will sustain their revenue improvement in 2024-2025 due to drug shortages in the United States. India is a hub of bulk generic drug manufacturing and drugmakers including Dr Reddy's, Cipla, Sun Pharma derive a significant share of revenue from both the US and Europe.

The world's largest drug market is facing decade-high drug shortages, India Ratings said in a note citing data from with Utah Drug Information Service.

There is an active shortage of 233 drugs across 22 therapeutic categories as of April, led mainly by discontinuing production of some drugs, rising demand and delays in shipments, it said, also citing data from the US Food and Drug Administration.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

Other Sports'It’s the combination more than anything else', says Agarkar on Gill’s axing from T20 WC squad

EntertainmentDivya Seth Shah documents her first day of shoot after losing daughter a year ago

InternationalCTA holds Tibet Outreach Programmes in Bengaluru to promote awareness on Tibetan history

NationalED arrests real estate firm MD in Rs 61 crore money laundering case

InternationalNASA loses contact with Mars probe 'Maven'

Business Realted Stories

BusinessRBI likely to pause rate cuts amid new CPI series unless growth falters: Report

BusinessBSE proposes cap on free order messages, plans charges beyond 10-crore daily limit

BusinessRBI issues compounding order for FEMA violations by Genpact India: ED

BusinessEnglishYaari Raises INR 1 Cr at INR 10 Cr Valuation; Bihar Startup Targets INR 50 Cr ARR by 2027

BusinessIndia’s AI talent base expected to more than double by 2027